10:48 AM EDT, 06/02/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said Monday that interim results for the ongoing phase 2 obesity study of semaglutide alone and in combination with trevogrumab, with or without garetosmab, showed the paired drugs helped preserve lean mass while boosting fat mass loss.

The interim analysis was conducted after half of the participants reached week 26 in the study, according to the company.

Discontinuations in the garetosmab arm were higher "due to tolerability issues and other adverse events, consistent with the safety profile previously seen with garetosmab alone," Regeneron said.

The company said that while 34.5% of the weight reduction in patients receiving only semaglutide was due to lean mass loss, this was lower in the combination groups, at 17% for the lower dose trevogrumab and 16.8% for the higher dose.

Price: 487.98, Change: -2.30, Percent Change: -0.47